Get the Stockscreener App
0.00
100.00%
-11.13
After Hours:
11.20
11.20
+
Verve Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$11.13
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$994.04M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
0.00
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$11.40
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
0.00 | 994.04M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Can you recover from losses in Verve Therapeutics Inc.Trade Entry Report & Expert Curated Trade Setup Alerts - newser.com
Is Verve Therapeutics Inc. stock a safe buy before earningsShort Setup & Daily Risk Controlled Trade Plans - newser.com
Price momentum metrics for Verve Therapeutics Inc. explainedJuly 2025 EndofMonth & Long-Term Safe Investment Ideas - newser.com
Can Verve Therapeutics Inc. stock withstand economic slowdownMarket Performance Report & Weekly Sector Rotation Insights - newser.com
Automated trading signals detected on Verve Therapeutics Inc.2025 Winners & Losers & Risk Managed Investment Strategies - newser.com
Verve Therapeutics Inc. stock daily chart insightsEarnings Risk Summary & Weekly Top Gainers Alerts - newser.com
How Verve Therapeutics Inc. stock benefits from global expansion2025 Price Momentum & Smart Money Movement Tracker - newser.com
How to track smart money flows in Verve Therapeutics Inc.CPI Data & Stepwise Swing Trade Plans - newser.com
Published on: 2025-10-24 04:58:14 - newser.com
Will Verve Therapeutics Inc. bounce back from current supportRecession Risk & Smart Swing Trading Techniques - newser.com
How to forecast Verve Therapeutics Inc. trends using time series2025 Pullback Review & Risk Controlled Daily Plans - newser.com
What dividend safety score for Verve Therapeutics Inc. stockTrade Performance Summary & Target Return Focused Stock Picks - newser.com
Verve Therapeutics Inc. stock retracement – recovery analysis2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
Applying big data sentiment scoring on Verve Therapeutics Inc.Quarterly Earnings Summary & Intraday High Probability Setup Alerts - newser.com
Will Verve Therapeutics Inc. stock see PE expansionWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
Ranking Verve Therapeutics Inc. among high performing stocks via tools2025 Key Highlights & Detailed Earnings Play Alerts - newser.com
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):